Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3162 in advanced solid tumors
NCT02759666Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Jun 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in solid tumor, sponsored by Atridia Pty Ltd. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Jun 2016; status: completed.
02
Drugs
fluzoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02759666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759666.